Category: Uncategorized

NAFLD Market and VK2809 Forecast The Non-Alcoholic Fatty Liver Disease (NAFLD) market is significant, valued at USD 2.01 billion in 2024, and is projected to reach USD 3.808 billion by 2035 with…

Rectal Budesonide Market Size and Forecast The Rectal Budesonide market is a niche but essential segment within the inflammatory bowel disease (IBD) therapeutic landscape, specifically targeting mild-to-moderate distal ulcerative colitis (UC). Its…

Transcription Activators Market Size and Forecast The global market for transcription activators is a niche yet rapidly expanding segment within biotechnology and pharmaceuticals. These activators, often focusing on gene regulation for therapeutic…

Olpasiran Market Size and Forecast Olpasiran is an investigational small interfering RNA (siRNA) therapy developed by Amgen, targeting lipoprotein(a) or Lp(a) levels. It is being studied for patients with established atherosclerotic cardiovascular…

Vaginal DHEA Market Size and Forecast The Vaginal DHEA market is a growing segment within the broader vaginal atrophy treatment landscape, addressing conditions like dyspareunia and vulvovaginal atrophy (VVA) associated with menopause….

Passive mAb for RSV Peds Market Size and Forecast The market for passive monoclonal antibody (mAb) prophylaxis against Respiratory Syncytial Virus (RSV) in pediatric populations is undergoing a significant transformation. Historically dominated…

HTN BBI-589 Market Size and Forecast HTN BBI-589 is anticipated to enter a highly competitive global market for hypertension treatments, a segment valued at billions of dollars annually due to the massive…

Implantable Rivastigmine Market Size and Forecast The Implantable Rivastigmine market is an emerging segment focused on delivering the Alzheimer’s treatment via long-acting implantable devices, contrasting with traditional oral or transdermal patches (which…

Thymoma and Pembrolizumab Market Size and Forecast The market for treatments targeting Thymoma, a rare tumor, is specialized, but the introduction of effective immunotherapies like Pembrolizumab is significantly shaping its value. While…

AF Abelacimab Market Size and Forecast Abelacimab is an investigational fully-human monoclonal antibody targeting Factor XI and Factor XIa, currently in Phase 3 trials for stroke prevention in atrial fibrillation (AF). The…